What Makes a "Breakthrough" Therapy? FDA Says More Details Are Coming
This article was originally published in RPM Report
Executive Summary
FDA’s Janet Woodcock believes the agency will be able to provide more concrete parameters around what constitutes a “Breakthrough” product in its final guidance document on the agency’s expedited programs. Maybe that will help lower the rate of denials.